Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 85/100

Failure Rate

22.2%

2 terminated/withdrawn out of 9 trials

Success Rate

60.0%

-26.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A

4(44.4%)

Phase 1

3(33.3%)

Phase 2

2(22.2%)

9Total

N/A(4)

Phase 1(3)

Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT00526253Phase 2Unknown

To Assess Safety and Efficacy of Myoblast Implantation Into Myocardium Post Myocardial Infarction

Role: lead

NCT03226093Not ApplicableCompleted

Safety Analysis of Implantation of Stromal Vascular Fraction

Role: lead

NCT03089762Phase 1Completed

Intra-articular Injection in the Knee of Adipose Derived Stromal Cells and Platelet Rich Plasma for Osteoarthritis

Role: lead

NCT02097862Not ApplicableCompleted

Adipose Cells for Degenerative Disc Disease

Role: lead

NCT02041000Not ApplicableWithdrawn

Adipose Derived Cells for Chronic Obstructive Pulmonary Disease

Role: lead

NCT02024269Not ApplicableWithdrawn

Study to Assess the Safety and Effects of Cells Injected Intravitreal in Dry Macular Degeneration

Role: lead

NCT00054678Phase 1Unknown

MYOHEART™ (Myogenesis Heart Efficiency and Regeneration Trial)

Role: lead

NCT00375817Phase 2Unknown

Safety and Effects of Implanted (Autologous) Skeletal Myoblasts (MyoCell) Using an Injection Catheter = SEISMIC Trial

Role: lead

NCT00050765Phase 1Unknown

Autologous Cultured Myoblasts (BioWhittaker) Transplanted Via Myocardial Injection

Role: lead

All 9 trials loaded